TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04371692

Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure

Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure

Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-Cov2 testing
Description: Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
Study: NCT02304289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Oral Artesunate once-daily for 14 days, dose-escalation
Study: NCT04371692

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-Cov2 testing
Description: Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-Cov2 testing
Description: Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
Study: NCT04439318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT01918059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesive skin closure
Description: The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Absorbable suture skin closure
Description: The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-absorbable suture skin closure
Description: The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
Study: NCT03222024

Intervention type: OTHER
Intervention: routine medical care
Description: This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study

Intervention type: OTHER
Intervention: routine medical care
Description: This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study

Intervention type: OTHER
Intervention: routine medical care
Description: This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
Study: NCT03028779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast-track Total Hip and knee arthroplasty
Description: To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
Study: NCT02474953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Curcumin Formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Curcumin Formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unformulated Comparator Curcumin Product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unformulated Comparator Curcumin Product
Study: NCT04597073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial Periodontal Therapy
Description: Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial Periodontal Therapy
Description: Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
Study: NCT00761527

Intervention type: DRUG
Intervention: Desloratadine Syrup
Description: Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~* Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg \[milligrams\] of desloratadine)~* Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~* Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)
Study: NCT02113358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous colloid bolus with Voluven

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous colloid bolus with Voluven
Study: NCT04036929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen-bazedoxifene
Description: Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study: NCT00051922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PolyEnv1
Description: Recombinant vaccinia virus vaccine
Study: NCT03036618

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa
Description: Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat
Description: Test wheat bread roll (approximately 160g weight) without quinoa.
Study: NCT03489928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Description: Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol
Description: Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
Study: NCT03938792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
Study: NCT03942939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time
Description: Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
Description: Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
Study: NCT01219062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: periarticular infiltration with 0.25% Bupivacaine for 20 ml.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
Study: NCT02339792

Intervention type: OTHER
Group type: OTHER
Intervention: E-learning
Description: e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)

Intervention type: OTHER
Group type: OTHER
Intervention: E-learning
Description: e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
Study: NCT01894438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle
Description: Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
Study: NCT03309930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehension Acquired Brain Injury
Description: For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
Study: NCT00541853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Candesartan upto 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan and Cilnidipine
Description: Candesartan upto 8mg per day and Cilnidipine upto 20mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan plus non-CCB agents
Description: Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
Study: NCT04328142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong group
Description: Traditional Chinese Medicine exercise programme

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy exercise programme
Study: NCT03969186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
Study: NCT03565835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
Study: NCT04248088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Stretching and Education
Description: 60 minutes of gentle stretching twice weekly for 6 months
Study: NCT01686282

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried Blueberry Powder
Description: 8 weeks of freeze-dried taken in two doses of 22g each per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of freeze-dried taken in two doses of 22g each per day.
Study: NCT04458753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee focused exercises
Description: Strengthening of quadriceps Stretching of calf and Hamstring muscles
Study: NCT04883034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block in outpatient clinic
Description: perform adductor canal block in outpatient clinic for patient post total knee arthroplasty

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesics, etoricoxibe
Description: anaelgetic oral intake
Study: NCT02859441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030
Description: E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
Study: NCT04458753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee focused exercises
Description: Strengthening of quadriceps Stretching of calf and Hamstring muscles
Study: NCT04426565

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: motivational enhancement interview
Description: Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: motivational enhancement interview
Description: Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: motivational enhancement interview
Description: Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
Study: NCT00303719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG.
Study: NCT00913926

Intervention type: DRUG
Intervention: E2/LNG oral (Wellnara, BAY86-5029)
Description: Patients in daily life treatment receiving Wellnara according to local drug information.
Study: NCT01900743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
Study: NCT00659230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepicastat
Description: 100-800mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100-800mg placebo
Study: NCT00861471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days.
Study: NCT00669383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone
Description: 12 mg IM q 24 hours x 2 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo IM q 24 hours x 2 doses
Study: NCT03742453

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: contrast-enhanced ultrasound
Description: CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EOB-MRI
Description: EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
Study: NCT04667546

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
Study: NCT02997982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500Mg Tablet
Description: Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
Study: NCT00269633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue Light Box 467 nm
Description: 467 nm Blue LED Light

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Red Light Box 657 nm
Description: 657 nm Red LED Light
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel
Study: NCT04426565

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: the individual psychotherapy
Description: It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: the individual psychotherapy
Description: It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
Study: NCT02419820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel
Study: NCT03568357

Intervention type: PROCEDURE
Intervention: Reoxygenation
Description: After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
Study: NCT02245256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: infusion of 0.1mcg/kg/hr of precedex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: placebo
Study: NCT02867540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI enterography
Study: NCT02410499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLN1202 Placebo
Description: MLN1202 placebo-matching solution for SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: MLN1202 solution for SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: MLN1202 solution for SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: MLN1202 solution for SC injection